Novacyt is scheduled to launch two PathFlow Covid-19 antigen lateral flow tests (LFTs), strengthening the company’s Covid-19 testing portfolio and expanding its footing in point-of-care solutions. The company is expected to initially target private market opportunities for these LFTs through its own distribution network. The new PathFlow Covid-19 antigen tests are small, instrument-free and enable safe sample collection, testing, reading and disposal by healthcare professionals or patients at their homes.
Avacta Group, a diagnostics and innovative cancer therapies developer, announced that a study found its AffiDX® antigen lateral flow test can successfully detect the Delta variant in clinical Covid-19 samples. This test also seemed to beat two other lateral flow antigen tests that are commercially available in Europe. Clinical data for Avacta’s test found it to have 100% sensitivity in detecting infectious individuals with viral loads of Ct<27 via a PCR test, where patients are considered to be contagious.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
BGI Americas, a diagnostic testing solutions provider, has entered into a partnership with Advaite, a biotech company, and announced the launch of dxpartnerships.com, a hub for diagnostics companies looking for partnerships based on licensing, distribution agreements and original equipment manufacturers. The partnership is expected to add Advaite’s RapCov rapid Covid-19 test to BGI’s portfolio of diagnostic testing solutions and combine Advaite’s handheld test with its real-time fluorescent RT-PCR kit for detecting SARS-CoV-2.
